 STATEN ISLAND, N.Y. , July 1, 2021 PRNewswire -- Acurx Pharmaceuticals, Inc. Nasdaq ACXP Acurx or the Company, a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that using specimens from a Phase 1 healthy volunteer trial and a novel analysis technique, beneficial changes potentially predictive of lower risk of CDI Clostridioides difficile Infection recurrence were associated with ibezapolstat compared to vancomycin. 